spacer
home > ebr > summer 2017 > acting up
PUBLICATIONS
European Biopharmaceutical Review

Acting Up

On January 4, 1983, President Reagan signed the Orphan Drug Act (ODA) into law with the goal of providing financial and marketing incentives so that private pharmaceutical companies would develop more therapeutics for rare diseases. The benefits offered by the ODA include seven years of marketing exclusivity upon approval, tax credits worth 50% of the cost of human clinical trials and federal research grants to fund the development of orphan drugs.

Today, critics question whether the ODA is being used appropriately by firms. Most of this discussion is centred around the ‘orphan subset’ – a subset of a relatively common disease that a narrowly-targeted therapy might be developed for to qualify as an orphan drug and reap the ODA’s protections and benefits. In February 2017, Senator Chuck Grassley opened an inquiry into potential abuses of ODA by drug sponsor; this inquiry is likely to investigate the practice of ‘salami-slicing’ and how this may contribute to high prices of orphan drugs.

Salami-Slicing


This practice is defined as “artificially subdividing diseases to create subgroups of patients that fall under the orphan drug prevalence threshold”.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthew Weinberg is Chief Executive Officer at The Weinberg Group. He guides all strategic issues with management client efforts, emphasising the provision of tactical and operational assistance to technically-oriented entities in areas including R&D, regulatory affairs and quality assurance. Matthew’s assignments have involved development of new products, testimony of the management and economics of scientific enterprises, contract issues and product advancement.

Emily Krulewitz is a Consultant at The Weinberg Group. Her work involves issues related to the development and regulation of therapeutics, medical devices, tobacco products and foods. Emily has experience in the preparation, coordination and compilation of regulatory submissions as well as responding to various legislative challenges through the development of technical reports. She received a bachelor’s degree in chemistry and integrated arts from Northwestern University, US, and a master’s degree in biotechnology from Johns Hopkins University, US.

spacer
Matthew Weinberg
spacer
spacer
spacer
Emily Krulewitz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

On Helix 2018

10-11 July 2018, The Cambridge Building, Babraham Research Campus

ON Helix is a two-day event aimed at informing delegates of how to turn early stage inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement